Clinical trial

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

NCT07349069

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention HRS-8080 Tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Letrozole tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tamoxifen Citrate Tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Anastrozole Tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Exemestane tablets Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-04

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

HRS-8080 TabletsDRUG

Letrozole tabletsDRUG

Tamoxifen Citrate TabletsDRUG

Anastrozole TabletsDRUG

Exemestane tabletsDRUG

Sponsors & collaborators

Shandong Suncadia Medicine Co., Ltd.lead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1 NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07349069 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.